US EditionNeuronetics Study Shows Strong Antidepressant Results for Teens and Young Adults Using NeuroStar TMS
Summary by MyChesCo
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Neuronetics Study Shows Strong Antidepressant Results for Teens and Young Adults Using NeuroStar TMS
MALVERN, PA — Neuronetics, Inc. (NASDAQ: STIM) announced new real-world data demonstrating that its NeuroStar transcranial magnetic stimulation (TMS) therapy delivers meaningful improvement in depression symptoms among adolescents and young adults. The findings, published in JAACAP Open, align with previously documented results in adult populations and highlight the potential of TMS as a safe, effective treatment option for younger patients. The…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
